Ability of online drug databases to assist in clinical decision-making with infectious disease therapies by Polen, Hyla H et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
Ability of online drug databases to assist in clinical decision-making 
with infectious disease therapies
Hyla H Polen*1, Antonia Zapantis2, Kevin A Clauson3, Jennifer Jebrock4 and 
Mark Paris5
Address: 1Nova Southeastern University, College of Pharmacy, Palm Beach Gardens, USA, 2Pharmacy Practice Department, Nova Southeastern 
University, College of Pharmacy, Fort Lauderdale, USA, 3Pharmacy Practice Department, Nova Southeastern University, College of Pharmacy – 
West Palm Beach, Palm Beach Gardens, USA, 4Broward General Medical Center and Nova Southeastern University, College of Pharmacy, Fort 
Lauderdale, USA and 5Infectious Disease Clinics, Palm Beach County Health Department, Delray Beach, USA
Email: Hyla H Polen* - polen@nova.edu; Antonia Zapantis - zapantis@nova.edu; Kevin A Clauson - clauson@nova.edu; 
Jennifer Jebrock - jennifer.jebrock@jhsmiami.org; Mark Paris - mparismd@gmail.com
* Corresponding author    
Abstract
Background: Infectious disease (ID) is a dynamic field with new guidelines being adopted at a rapid rate. Clinical
decision support tools (CDSTs) have proven beneficial in selecting treatment options to improve outcomes.
However, there is a dearth of information on the abilities of CDSTs, such as drug information databases. This
study evaluated online drug information databases when answering infectious disease-specific queries.
Methods: Eight subscription drug information databases: American Hospital Formulary Service Drug Information
(AHFS), Clinical Pharmacology (CP), Epocrates Online Premium (EOP), Facts & Comparisons 4.0 Online (FC),
Lexi-Comp (LC), Lexi-Comp with AHFS (LC-AHFS), Micromedex (MM), and PEPID PDC (PPDC) and six freely
accessible: DailyMed (DM), DIOne (DIO), Epocrates Online Free (EOF), Internet Drug Index (IDI), Johns Hopkins
ABX Guide (JHAG), and Medscape Drug Reference (MDR) were evaluated for their scope (presence of an
answer) and completeness (on a 3-point scale) in answering 147 infectious disease-specific questions. Questions
were divided among five classifications: antibacterial, antiviral, antifungal, antiparasitic, and vaccination/
immunization. Classifications were further divided into categories (e.g., dosage, administration, emerging
resistance, synergy, and spectrum of activity). Databases were ranked based on scope and completeness scores.
ANOVA and Chi-square were used to determine differences between individual databases and between
subscription and free databases.
Results: Scope scores revealed three discrete tiers of database performance: Tier 1 (82-77%), Tier 2 (73-65%)
and Tier 3 (56-41%) which were significantly different from each other (p < 0.05). The top tier performers: MM
(82%), MDR (81%), LC-AHFS (81%), AHFS (78%), and CP (77%) answered significantly more questions compared
to other databases (p < 0.05). Top databases for completeness were: MM (97%), DM (96%), IDI (95%), and MDR
(95%). Subscription databases performed better than free databases in all categories (p = 0.03). Databases suffered
from 37 erroneous answers for an overall error rate of 1.8%.
Conclusion: Drug information databases used in ID practice as CDSTs can be valuable resources. MM, MDR,
LC-AHFS, AHFS, and CP were shown to be superior in their scope and completeness of information, and MM,
AHFS, and MDR provided no erroneous answers. There is room for improvement in all evaluated databases.
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Background
Timely access to clinical decision support tools (CDSTs)
has proven beneficial in selecting appropriate treatment
options that result in improved therapeutic outcomes [1-
6]. The use of such aids as personal digital assistants
(PDAs), computerized physician order entry (CPOE),
electronic health records (EHRs), and electronic databases
has shown positive influence on patient morbidity and
mortality, cost management and formulary compliance,
and prevention of medication errors and related fatalities
[3,7-13]. The arena of infectious disease (ID) is a complex
and dynamic field with new treatment guidelines being
adopted and innovative pharmaceutical options being
introduced at a rapid rate. As such, ID management has a
great potential for medication errors [14-16]. In fact, ID
has benefited greatly from these innovative tools
[3,17,18] both as a method to keep abreast of these rapid
changes and as a mechanism to assist practitioners in
understanding and embracing the most contemporary
and appropriate therapies.
There is a dearth of information in the literature providing
guidance to ID healthcare providers on the abilities of
CDSTs, such as drug information databases, to provide
the information most needed in this specialized practice
setting. To date, no evaluations have been published that
evaluated the ID content in online drug information data-
bases, and only one study has been conducted that exam-
ined ID-specific drug information content in selected PDA
programs. Miller et al. [19] evaluated four ID programs for
PDAs, including: Epocrates ID, Johns Hopkins ABX
Guide, Sanford's Guide to Antimicrobial Therapy, and
Infectious Diseases and Antimicrobials Notes. This study
focused on the salient features, advantages, disadvantages,
and hardware and software requirements of each of these
four databases. The evaluation of the scope and accuracy
of the references' drug information was limited to a com-
parison of the monographs contained in each database to
the information contained in the package insert for a sin-
gle drug, fluconazole. Based on this narrow evaluation
methodology, the study found that while each program
contained the information physicians needed most at the
point-of-care, such as dosing, adverse events, and drug
interactions for antimicrobials, all of the applications had
limited pharmacological and pharmacokinetic informa-
tion. Some of the databases omitted important topics like
pediatric dosing, contraindications, precautions, and
adverse reactions. The authors concluded the use of PDA
applications may decrease prescriptions errors, lead to sig-
nificant improvements in patient outcomes, and cost
reduction despite the identified shortcomings.
ID-specific PDA programs provide an important avenue
for clinical decision support, especially for counsel
needed at point-of-care. The question is: do they provide
enough information about all aspects of pharmaceutical
prescribing and management that specialty practitioners
require? Utilization of online subscription or free drug
information databases is an alternative to assist healthcare
providers in making timely and accurate ID treatment
determinations that encompass a plethora of medication
topics relevant to patient care and treatment outcomes. ID
practitioners have several products from which to choose
and a multitude of factors must be weighed before making
a decision on which online database best meets the user's
needs. While several previous studies have been con-
ducted to determine the abilities of online databases to
satisfy the general drug information needs of healthcare
providers [20-23], this study helps to elucidate the differ-
ences in selected online drug databases and compares the
effectiveness of each CDST's ability to perform for an ID
specialty setting. This study specifically aimed to evaluate
the ability of online drug information databases to pro-
vide clinical decision support when answering infectious
disease-specific queries.
Methods
Database selection
To be considered for inclusion, databases had to be acces-
sible online and could either be designed as general drug
information databases or ID-specific drug information
databases. A list of references for consideration was com-
piled based on previous database studies [20-23], input
from an expert panel, and utilization by current practi-
tioners. Programs were included if the monographs were
able to answer a diverse set of medication-related inquir-
ies, including such topics as indications, adverse drug
events, and drug interactions. Databases were excluded if
they were intended exclusively for a particular practice set-
ting other than ID, such as nursing, oncology, or pediat-
rics. Other references that were not designed primarily as
drug information databases (e.g., Sanford's Guide to Anti-
microbial Therapy and The 5 Minute Infectious Diseases
Consult) were similarly excluded. Databases limited to
answering a specific drug information question-type (e.g.,
drug interactions, compatibility/stability) were also omit-
ted. Fourteen databases met the inclusion requirements:
eight subscription and six freely accessible. Only one ID-
specific database, Johns Hopkins ABX Guide, was identi-
fied that met the inclusion criteria. The subscription data-
bases included American Hospital Formulary Service
Drug Information (AHFS), Clinical Pharmacology (CP),
Epocrates Online Premium (EOP), Facts & Comparisons
4.0 Online (FC), Lexi-Comp (LC), Lexi-Comp with AHFS
(LC-AHFS), Micromedex (MM), and PEPID PDC (PPDC).
The six freely accessible databases included: DailyMed
(DM), DIOne (DIO), Epocrates Online Free (EOF), Inter-
net Drug Index–RxList.com (IDI), Johns Hopkins ABX
Guide (JHAG), and Medscape Drug Reference (MDR).BMC Infectious Diseases 2008, 8:153 http://www.biomedcentral.com/1471-2334/8/153
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Table 1 provides publisher and website details for each
database included in this study.
Related databases
Lexi-Comp, Inc. offers two different versions of their drug
information database: LC, which is a compilation of their
standard drug monographs and LC-AHFS, which contains
their standard monographs plus the information availa-
ble in AHFS. Because of the potential similarity between
AHFS, LC, and LC-AHFS, a subgroup analysis was per-
formed to assess statistical differences between the data-
bases.
Category design
Five general treatment classifications were created based
on a review of ID-related Anatomical Therapeutic Chemi-
cal (ATC) classification codes as listed on the 14th World
Health Organization (WHO) Model List of Essential Med-
icines: antibacterial, antiviral, antifungal, antiparasitic,
and vaccination/immunization. These classifications were
weighted based on importance of such factors as preva-
lence and incidence of infection type, morbidity and mor-
tality data, and resistance patterns in the USA as reported
by the Morbidity and Mortality Weekly Report (MMWR)
and WHO. Within each of these classifications, 16 differ-
ent drug information categories were designed, including
dosage, interactions, emerging resistance, and spectrum of
activity. Additionally, these categories were weighted
based on their impact on direct patient care and impor-
tance to patient safety. For example, dosage and adminis-
tration were considered more clinically relevant and thus
weighted heavier, than categories less influential on direct
patient care and safety such as cost and pharmacokinetics.
Classification and category information, including
weighting of each, is shown in Table 2.
Question development
In order to have a greater likelihood of determining dif-
ferences among the databases, a robust number of ques-
tions was needed. The most highly weighted categories
Table 1: Database publishers and website addresses
Database name Abbreviation used in study Publisher Website
American Hospital Formulary Service 
Drug Information
AHFS American Society of Health-System 
Pharmacists
http://www.ashp.org/ahfs
Clinical Pharmacology CP Gold Standard http://
www.clinicalpharmacology.com
DailyMed DM National Library of Medicine http://dailymed.nlm.nih.gov/
dailymed
DIOne DIO Pharmacy OneSource, Inc. http://
www.pharmacyonesource.com
Epocrates Online Free EOF Epocrates, Inc. http://www.epocrates.com
Epocrates Online Premium EOP Epocrates, Inc. http://www.epocrates.com
Facts & comparisons 4.0 Online FC Wolters Kluwer Health http://
www.factsandcomparisons.com
Internet Drug Index IDI WebMD http://www.rxlist.com
Johns Hopkins ABX Guide JHAG Johns Hopkins University http://www.hopkins-abxguide.org
Lexi-Comp LC Lexi-Comp, Inc. http://www.lexi.com
Lexi-Comp with American Hospital 
Formulary Service
LC-AHFS Lexi-Comp, Inc. http://www.lexi.com
Medscape Drug Reference MDR Medscape, LLC http://www.medscape.com
Micromedex MM Thomson Healthcare http://www.micromedex.com
PEPID PDC PPDC PEPID, LLC http://www.pepid.comBMC Infectious Diseases 2008, 8:153 http://www.biomedcentral.com/1471-2334/8/153
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Table 2: Weighting of classifications and categories
CATEGORY N (%) VIRAL BACTERIAL FUNGAL PARASITIC VACCINATION/
IMMUNIZATION
Dosing 15 (10) 4 4 3 2 2
Indication 15 (10) 4 4 3 2 2
Adverse reaction/event 13 (9) 3 3 3 2 2
Contraindications 13 (9) 3 3 3 2 2
Drug-Drug Interactions 12 (8) 3 3 3 2 1
Emerging Resistance 12 (8) 4 4 2 1 1
Administration 10 (7) 3 3 2 1 1
Mechanism of action 9 (6) 2 2 2 2 1
Food-Drug Interactions 7 (5) 2 2 1 1 1
Compatibility/Stability 7 (5) 2 2 1 1 1
Spectrum of Activity 7 (5) 2 2 1 1 1
Pregnancy/Lactation 7 (5) 2 2 1 1 1
Synergy 6 (4) 2 2 1 1 0
Drug-Herb Interactions 5 (3) 1 1 1 1 1
Cost 5 (3) 1 1 1 1 1
Pharmacokinetics 4 (3) 1 1 1 1 0
TOTAL 147 (100) 39 39 29 22 18
Table 3: Sample questions and answers used in evaluation
How is tenofovir dosing adjusted for a hemodialysis patient? Tenofovir should be dosed at 300 mg every 7 days or after a total of approximately 12 
hours of hemodialysis. Dose should be given after hemodialysis session.
Should sulfadiazine be used alone for toxoplasmosis prophylaxis? No. It should be used in conjunction with pyrimethamine and leucovorin.
What are the electrolyte abnormalities associated with Amphotericin B? Decreased magnesium, decreased calcium, and decreased or increased 
potassium.
Can nitazoxanide suspension be given safely to diabetic patients? Diabetics should be aware that the suspension contains 1.48 grams of sucrose per 
5 mL.
What three drugs have cases reporting increased levels when administered with Fluzone? Phenytoin, warfarin, and theophylline.
What specific resistance profile has been documented in an HIV/HBV patient taking entecavir? M184V resistance substitution has occurred in the 
HIV strain.
What is used to reconstitute ertapenem for intramuscular administration? 3.2 mL of 1% Lidocaine HCl injection (without epinephrine).
What preservative does the Pneumovax pneumococcal vaccine contain? Phenol 0.25%.
How does spinal fluid concentrations of amikacin compare to serum concentrations in infants? Spinal fluid levels in normal infants are approximately 
10 to 20% of the serum concentrations and may reach 50% when the meninges are inflamed.
What is the spectrum of activity of acyclovir? Herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV).
Can metronidazole be given to pregnant patients with trichomoniasis? It is contraindicated during the 1st trimester of pregnancy due to lack of 
clinical evidence.
Against what viruses have foscarnet and ganciclovir shown a synergistic effect both in vitro and in vivo? Cytomegalovirus and herpes simplex virus 
type 2.
Why should willow bark be avoided 6 weeks after receiving Varivax? Because Reye's Syndrome has been reported following natural varicella 
infection.BMC Infectious Diseases 2008, 8:153 http://www.biomedcentral.com/1471-2334/8/153
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were therefore assigned a total of 15 questions, and sub-
sequent categories were populated with a stepwise reduc-
tion in the number of questions based on their weighted
percentages. A set of 147 ID-specific question and
answer pairs were developed and divided across the five
ID classification categories and the 16 drug information
categories. Answers were determined using manufacturer
package inserts and primary literature, as well as gold
standard references including the MMWR [24], Centers
for Disease Control and Prevention (CDC) [25], Princi-
ples and Practices of Infectious Disease [26], and Natural
Medicine Comprehensive Database [27]. The author-
developed study design and question and answer set
were reviewed by an external panel of ID physicians and
pharmacists for accuracy and relevance to clinical prac-
tice. The question list was then finalized based on the
panel recommendations. A sample of questions and
answers is provided in Table 3.
Database assessment
Databases were evaluated for their ability to answer each
of the 147 questions and the completeness of the answers
that the databases were able to provide. The presence or
absence of the answer (scope) was determined, and a
score of one was assigned for scope if the database pro-
vided the answer or a score of zero was assigned if the
answer was absent. Answer completeness was determined
using a 3-point scale, with three being the most complete
and one being the least. Questions were structured in such
a way that differences in completeness could be detected,
often containing more than one part to the answer.
Answers with only one part (e.g., Can valacyclovir be
given to treat herpes encephalitis? No) would receive a
three for completeness if the answer was present. If an
answer had two components (e.g., What are the concerns
with ceftriaxone administration in neonates? May dis-
place bilirubin and cannot be administered with calcium-
containing solutions due to risk of ceftriaxone-calcium
precipitation) then completeness would be scored either a
two if one answer was present or a three if both answers
were present. For questions requiring three or more com-
ponents to provide a complete answer, the completeness
score was assigned a three if all components were present
(e.g., What are the visual disturbances associated with vor-
iconazole? Abnormal vision, color vision change, and/or
photophobia). Completeness scores were only assigned if
there was a score for scope. Assessments were made inde-
pendently by at least two authors for two consecutive
months ending in November 2007. In the three instances
where the results were disparate, a consensus was reached
on score assignation by the authors. Erroneous answers
that were provided by the databases were also docu-
mented.
Statistical analysis
Data were summarized using descriptive statistics to
obtain rank order of databases based on scope and com-
pleteness scores. Inferential statistics were used to deter-
mine differences between individual databases and
between subscription and free databases, via both ANOVA
and Chi-square tests as appropriate. Tukey-Kramer's mul-
tiple comparison post-hoc tests were used to differentiate
among databases. Similar analyses were conducted to
determine statistical differences between AHFS, LC and
LC-AHFS, as well as subscription and free versions of
Epocrates. P values below 0.05 were considered statisti-
cally significant. This study was approved by the Health
Professions Division Research Committee of Nova South-
eastern University.
Results
Scope
Pair-wise comparisons of scope scores revealed three dis-
crete tiers of database performance including: Tier 1
(Scope 82-77%), Tier 2 (Scope 73-65%) and Tier 3 (Scope
56-41%) which were all significantly different from each
other (p < 0.05). The top tier performers: MM (82%),
MDR (81%), LC-AHFS (81%), AHFS (78%), and CP
(77%) answered significantly more questions when com-
pared to the other databases (p < 0.05). The middle group
of database scores (Tier 2) was: FC (73%), IDI (71%),
DIO (65%), DM (65%), and LC (65%), and the lowest
tier databases were: JHAG (56%), EOP (47%), EOF
(46%), and PPDC (41%). Full details for database scores
for scope across all categories and databases are included
in Table 4.
Completeness
Similar to the scores for scope, results for completeness
were stratified into three distinct tiers including: Tier 1
(97-89%), Tier 2 (83-81%), and Tier 3 (74%), which were
all significantly different from each other (p < 0.05). The
top scoring databases for completeness were MM (97%),
DM (96%), IDI (95%), MDR (95%), AHFS (94%), CP
(94%), FC (94%), LC-AHFS (94%), and DIO (89%). Mid-
ranking databases (Tier 2) were LC (83%), JHAG (82%),
EOF (81%), and EOP (81%). PPDC (74%) scored in the
lowest tier. Full results for completeness scores, including
scores in each drug information category, are provided in
Table 5.
Categorical analysis
When exclusively examining differences in the ability to
answer questions (scope) in the ID categories, subscrip-
tion databases performed better within both the ID-spe-
cific and non-ID specific categories than the free databases
(p = 0.03). ID-specific categories included emerging resist-
ance, spectrum of activity, and synergy. However, there
was no difference between free and subscription onlineBMC Infectious Diseases 2008, 8:153 http://www.biomedcentral.com/1471-2334/8/153
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databases in scope between individual categories (e.g.,
dosing, administration, etc.). Comparisons of scope and
completeness scores between free and subscription data-
bases are shown in Figures 1 and 2, respectively.
Sub-analysis of related databases
While no differences in scope were found between AHFS
and LC-AHFS, both databases answered more questions
than LC alone (p < 0.05). Similar findings were seen in
Table 4: Scope of databases
CATEGORY N (147) AHFS CP DIO DM EOF EOP FC IDI JHAG LC LC-AHFS MDR MM PPDC
Dosing 15 12 11 12 10 6 6 12 12 8 12 12 12 13 6
Indication 15 13 11 11 5 6 6 9 7 11 13 13 14 15 7
Adverse Reaction/Event 13 9 12 8 10 6 6 11 11 8 8 9 9 11 4
Contraindications 13 12 9 10 8 8 8 9 8 5 11 12 10 12 5
Drug-Drug Interactions 12 11 12 10 10 11 11 10 10 6 10 11 12 10 10
Emerging Resistance 12 8 9 4 10 0 0 9 10 6 2 8 9 10 0
Administration 10 10 8 8 8 6 6 10 10 7 9 10 10 9 4
Mechanism of Action 9 8 9 8 6 8 8 9 7 7 7 8 8 7 7
Food-Drug Interactions 7 7 5 4 4 2 2 4 4 3 4 7 5 4 2
Compatibility/Stability 7 4 4 0 3 0 0 4 4 0 3 4 5 4 0
Spectrum of Activity 7 5 6 4 5 3 3 5 5 6 4 5 5 7 4
Pregnancy/Lactation 7 5 7 6 5 5 5 6 6 5 5 7 6 6 5
Synergy 6 6 5 4 5 3 3 5 4 4 3 6 6 6 3
Drug-Herb Interactions 5 2 2 1 2 0 2 1 2 1 1 2 2 3 2
Cost 5 0 0 3 0 2 2 0 0 3 2 2 3 0 0
Pharmacokinetics 4 3 3 3 4 1 1 4 4 2 2 3 3 4 1
Percent Answered (%) 78 77 65 65 46 47 73 71 56 65 81 81 82 41
N = number of questions; AHFS = American Hospital Formulary Service Drug Information; CP = Clinical Pharmacology; DIO = DIOne; DM = 
DailyMed; EOF = Epocrates Online Free; EOP = Epocrates Online Premium; FC = Facts & Comparisons 4.0 Online; IDI = Internet Drug Index; 
JHAG = Johns Hopkins ABX Guide; LC = Lexi-Comp; LC-AHFS = Lexi-Comp with American Hospital Formulary Service; MDR = Medscape Drug 
Reference; MM = Micromedex, PPDC = PEPID PDC
Table 5: Completeness of databases
CATEGORY AHFS CP DIO DM EOF EOP FC IDI JHAG LC LC-AHFS MDR MM PPDC
Dosing 3.00 3.00 2.83 3.00 2.17 2.17 2.92 2.92 2.38 2.67 2.92 2.92 3.00 2.83
Indication 2.85 2.73 2.91 3.00 2.50 2.50 2.89 3.00 2.55 2.62 2.85 2.86 3.00 2.29
Adverse Reaction/Event 2.78 2.83 2.88 2.90 2.83 2.83 2.91 2.91 2.63 2.76 2.78 2.78 3.00 2.75
Contraindications 3.00 3.00 2.50 2.88 2.50 2.50 3.00 2.75 2.00 2.36 2.92 3.00 2.92 2.40
Drug-Drug Interactions 2.82 2.83 2.50 3.00 2.64 2.64 2.30 2.70 1.83 2.30 2.82 2.92 2.90 1.70
Emerging Resistance 2.75 2.67 3.00 3.00 N/A N/A 3.00 3.00 2.67 2.00 2.88 2.89 3.00 N/A
Administration 3.00 3.00 2.63 3.00 2.67 2.67 2.90 2.90 2.67 2.56 3.00 2.90 3.00 2.50
Mechanism of Action 2.88 3.00 2.25 2.83 1.88 1.88 2.67 2.86 2.86 2.14 2.88 2.88 2.57 1.86
Food-Drug Interactions 2.43 2.80 2.50 2.75 2.00 2.00 3.00 3.00 2.33 2.75 2.43 2.60 3.00 N/A
Compatibility/Stability 3.00 2.50 N/A 2.67 N/A N/A 2.75 2.75 N/A 2.33 3.00 3.00 3.00 N/A
Spectrum of Activity 3.00 2.67 3.00 3.00 2.33 2.33 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00
Pregnancy/Lactation 2.40 2.86 2.33 2.20 2.00 2.00 2.67 2.50 2.40 2.80 2.57 2.00 2.50 1.80
Synergy 2.67 2.60 2.50 2.80 3.00 3.00 2.40 3.00 2.50 2.00 2.67 3.00 2.67 2.67
Drug-Herb Interactions 2.50 2.50 3.00 2.00 N/A 2.00 3.00 1.50 2.00 1.00 2.50 2.50 2.67 2.00
Cost N/A N/A 3.00 N/A 3.00 3.00 N/A N/A 3.00 3.00 3.00 3.00 N/A N/A
Pharmacokinetics 3.00 3.00 2.33 3.00 2.00 2.00 3.00 2.75 2.50 2.00 3.00 3.00 3.00 2.00
(%) 94 94 89 96 81 81 94 95 82 83 94 95 97 74
N = number of questions; AHFS = American Hospital Formulary Service Drug Information; CP = Clinical Pharmacology; DIO = DIOne; DM = 
DailyMed; EOF = Epocrates Online Free; EOP = Epocrates Online Premium; FC = Facts & Comparisons 4.0 Online; IDI = Internet Drug Index; 
JHAG = Johns Hopkins ABX Guide; LC = Lexi-Comp; LC-AHFS = Lexi-Comp with American Hospital Formulary Service; MDR = Medscape Drug 
Reference; MM = Micromedex, PPDC = PEPID PDC; N/A = not applicableBMC Infectious Diseases 2008, 8:153 http://www.biomedcentral.com/1471-2334/8/153
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regards to completeness, where AHFS and LC-AHFS were
more complete in answering the questions than LC alone
(p < 0.05), but no difference was found between AHFS
and LC-AHFS. When comparing EOF and EOP databases,
no differences in scope or completeness (p > 0.05) were
seen.
Errors
There were 37 erroneous answers found in this analysis
yielding an overall error rate of 1.8%. Of the fourteen
databases evaluated, three databases had no errors (MM,
AHFS, and MDR), four had two errors (DM, FC, LC, and
LC-AHFS), four had three errors (CP, DIO, IDI, and
JHAG), and five errors were found in both versions of
Epocrates. PPDC had seven wrong answers, which was
found to be significantly higher than the other databases
(p < 0.05). A summary of errors in each category is shown
in Table 6, and a sample of erroneous answers that have
the potential to impact clinical outcomes and patient
safety has been provided in Table 7.
Discussion
In a field as dynamic and evolving as ID, the use of CDSTs,
such as drug information databases, can improve patient
Table 6: Errors by database and errors per category
CATEGORY N AHFS CP DIO DM EOF EOP FC IDI JHAG LC LC-AHFS MDR MM PPDC TOTAL 
ERRORS 
PER 
CATEGORY
Dosing 15 - - - - - - - - 2 - - - - 2 4
Indication 15 - 2 1 1 - - 1 - 1 1 1 - - 3 11
Adverse Drug 
Reaction
13 - - - - 2 2 - 2 - - - - - - 6
Contraindicati
ons
13 - - 1 1 1 1 1 1 - 1 1 - - 1 9
Method of 
Administration
10 - 1 - - 1 1 - - - - - - - 1 4
Drug-Food 
Interactions
7- -1-11- - - - - - - - 3
TOTAL 
ERRORS 
PER 
DATABASE
03 3 2 55 2 332 2 00 7
N = number of questions; AHFS = American Hospital Formulary Service Drug Information; CP = Clinical Pharmacology; DIO = DIOne; DM = 
DailyMed; EOF = Epocrates Online Free; EOP = Epocrates Online Premium; FC = Facts & Comparisons 4.0 Online; IDI = Internet Drug Index; 
JHAG = Johns Hopkins ABX Guide; LC = Lexi-Comp; LC-AHFS = Lexi-Comp with American Hospital Formulary Service; MDR = Medscape Drug 
Reference; MM = Micromedex, PPDC = PEPID PDC
Scope comparison of drug information categories between  subscription and free databases Figure 1
Scope comparison of drug information categories 
between subscription and free databases.
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Mechanism of Action
Method of Administration
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Pharmacokinetics
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Emerging Resistance
Compatibility/Stability
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Completeness comparison of drug information categories  between subscription and free databases Figure 2
Completeness comparison of drug information cate-
gories between subscription and free databases.
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Emerging Resistance
Compatibility/Stability
Drug-Herb Interaction
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safety and clinical outcomes. However, a reference is only
as good as the information it contains and this study
revealed that improvements are necessary. Several general
drug information databases were able to provide superior
depth and breadth of information, while other references
did not perform as well. MM (82%), MDR (81%), LC-
AHFS (81%), AHFS (78%), and CP (77%) were all top
performers, but even the database with the highest score
for scope (MM) was unable to answer nearly one-fifth of
the evaluative questions, and the database with the lowest
scope score (PPDC) fell short by almost 60%. This deficit,
in practical terms, shows that MM would be unable to
provide an answer to one out of every five drug informa-
tion queries, and PPDC would be unable to provide an
answer to three out of every five. This disparity between
the information needed by the healthcare professional
and the information provided by the resources could have
a far-reaching negative effect on both practical utility and
clinical outcomes.
Not providing a sufficient scope of information is not as
critical as providing accurate information. If an answer is
not found, the healthcare provider can turn to another
resource to locate the answer. But, if a wrong answer is
given, the provider may not realize that the information is
unreliable and use it to make a critical decision, poten-
tially resulting in a negative outcome or even patient
harm. The number of errors (1.8%) found amongst the
databases was alarming. Out of the 14 references evalu-
ated, only three (i.e. MM, AHFS, and MDR) returned no
erroneous answers. Of the drug information categories in
which errors were found, two (dosing and indication)
Table 7: Sample of erroneous answers discovered in databases
Category Question Correct answer used for 
assessment
Erroneous answer(s) Database(s)
Dosing What is the recommended 
dosing regimen for 
fosamprenavir in a protease 
inhibitor-experienced HIV+ 
patient who wants once daily 
dosing?
Once daily dosing is not 
recommended for this type of 
patient
• 700 mg by mouth once daily plus 
ritonavir 100 mg twice daily for PI 
experienced patients
￿ PPDC
Adverse Drug Reaction Can ethionamide cause 
impotence?
Yes, but it is a rare ADR. ￿ Listed as a common reaction ￿ JHAG
Method of Administration How do you administer 
Synagis?
Remove flip top from Synagis 
vial and wipe rubber stopper 
with a disinfectant (e.g., 70% 
isopropyl alcohol). Insert 
needle into vial, and withdraw 
into syringe an appropriate 
volume of solution. Administer 
immediately after drawing dose 
into syringe. Synagis is supplied 
as single-dose vial and does not 
contain preservatives. Do not 
re-enter vial after withdrawal of 
drug; discard unused portion. 
Only administer one dose per 
vial.
￿ Provides information about 
scheduling multiple patients for 
multiple injections from same vial 
to minimize waste
￿ CP
Indication Should amantadine be given as 
prophylaxis against influenza 
A?
It should not be used in the 
2007–2008 influenza season 
due to resistance.
￿ Provides pediatric dosing 
information for this indication
￿ Lists influenza A prophylaxis as 
an indication
￿ PPDC
￿ DM
￿ IDI
Drug-Food interaction How should didanosine be 
taken in regards to food?
Didanosine should be taken on 
an empty stomach at least 30 
minutes before or 2 hours after 
food. Do not take didanosine 
or didanosine EC with food.
￿ Provides contradictory 
information: States that didanosine 
can be taken with or without food 
in one sentence and the following 
statement states to take on an 
empty stomach 30 minutes before 
or 2 hours after food.
￿ EOF
￿ EOP
￿ DIO
CP = Clinical Pharmacology; DIO = DIOne; DM = DailyMed; EOF = Epocrates Online Free; EOP = Epocrates Online Premium; IDI = Internet Drug 
Index; JHAG = Johns Hopkins ABX Guide; PPDC = PEPID PDCBMC Infectious Diseases 2008, 8:153 http://www.biomedcentral.com/1471-2334/8/153
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were deemed so important to direct patient care and
patient safety that they were the top two weighted catego-
ries in this study, both with 15 questions (10.2%) each.
While some of the errors were blatantly wrong, others
were instances where the database gave information that
was not in line with that provided by the manufacturer
but may be acceptable in current clinical practices. CDSTs
have been proven to be useful in making timely and accu-
rate patient care decisions at all stages of the decision-
making process, but this study has shown that CDTSs can-
not be considered reliable all of the time. Healthcare pro-
viders, in all aspects of practices, are expected to be
accurate 100% of the time in order to ensure patient
safety. This goal cannot be achieved if the tools that are
used in the course of practice are not held to that same
high standard.
Limitations
Our study had several potential limitations. The evalua-
tive questions used were intended to be a subset of all pos-
sible drug information questions. While we were careful
to represent as many types of drug information questions
as possible, inclusion of all clinical aspects was not feasi-
ble. Performing the same evaluation with a different set of
questions could produce different results; however,
because of the broad range of scenarios represented in the
original question list, the results would most likely yield
little or no differences. Also, our study captured the data
available from the databases at a set point in time, but the
databases are tools that are updated with varying fre-
quency. It is possible that changes have been made to the
information contained in the databases since the time of
this evaluation. And finally, some publishers offer addi-
tional components with their drug information databases
(e.g., dose calculators). If these value-added features
required an additional purchase, they were not used for
this evaluation.
Conclusion
Drug information databases used in ID practices as CDSTs
can be valuable resources for the healthcare provider.
MM, MDR, LC-AHFS, AHFS, and CP were shown to be
superior in their scope and completeness of information,
and MM, AHFS, and MDR provided no erroneous
answers. There is room for improvement in all databases
evaluated in this study.
Competing interests
HHP, AZ, JJ, and MP declare that they have no competing
interests. KAC has received grant support from Elsevier
Science/Gold Standard, Inc. which produces Clinical
Pharmacology.
Authors' contributions
HHP conceived the project, developed the study design,
wrote the question list, performed data collection, and
wrote and critically edited the manuscript. AZ contributed
to the study design and question list, conducted the statis-
tical analysis, and wrote and critically edited the manu-
script. KAC contributed to the study design and wrote and
critically edited the manuscript. JJ wrote the question list,
assisted with data collection, and critically edited the
manuscript. MP assisted in question development and
critically edited the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The authors wish to acknowledge the clinical insight and input provided by 
Raquel Mateo-Bibeau, MD and Jerri Jean Stambaugh, Pharm.D., as well as 
assistance with the statistical analysis and interpretation of results by Wil-
liam R. Wolowich, Pharm.D.
References
1. Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T,
Hallisey R, Ives J, Laird N, Laffel G, et al.:  Systems analysis of
adverse drug events. ADE Prevention Study Group.  JAMA
1995, 274:35-43.
2. Kohn LT, Corrigan JM, Donaldson MS, Institute of Medicine: To err
is human: building a safer health system.  Washington, DC:
National Academy Press; 2000. 
3. Sintchenko V, Iredell JR, Gilbert GL: Comparative impact of
guidelines, clinical data, and decision support on prescribing
decisions: an interactive web experiment with simulated
cases.  J Am Med Inform Assoc 2004, 11:71-7.
4. Leape LL, Berwick DM: Five years after To Err Is Human: what
have we learned?  JAMA 2005, 293:2384-90.
5. Partin B: Preventing medication errors: an IOM Report.  Nurse
Pract 2006, 31:8.
6. Greenfield S: Medication error reduction and the use of PDA
technology.  J Nurs Educ 2007, 46:127-31.
7. Bates DW, Kuperman GJ, Wang S, Gandhi T, Kittler A, Volk L, et al.:
Ten commandments for effective clinical decision support:
making the practice of evidence-based medicine a reality.  J
Am Med Inform Assoc 2003, 10:523-30.
8. Fernandopulle R, Ferris T, Epstein A, McNeil B, Newhouse J, Pisano
G, et al.: A research agenda for bridging the 'quality chasm.'.
Health Aff (Millwood) 2003, 22:178-90.
9. Kaushal R, Shojania KG, Bates DW: Effects of computerized phy-
sician order entry and clinical decision support systems on
medication safety: a systematic review.  Arch Intern Med 2003,
163:1409-16.
10. Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux
PJ, Beyene J, et al.: Effects of computerized clinical decision sup-
port systems on practitioner performance and patient out-
comes: a systematic review.  JAMA 2005, 293:1223-38.
11. Teich JM, Osheroff JA, Pifer EA, Sittig DF, Jenders RA, The CDS
Expert Review Panel: Clinical decision support in electronic
prescribing: recommendations and an action plan: report of
the joint clinical decision support workgroup.  J Am Med Inform
Assoc 2005, 12:365-76.
12. Javitt JC, Rebitzer JB, Reisman L: Information technology and
medical missteps: evidence from a randomized trial.  J Health
Econ 2008, 27:585-602.
13. Johnston D, Pan E, Middleton B, Walker J, Bates DW: The value of
computerized CPOE in ambulatory settings.   [ h t t p : / /
www.citl.org/research/ACPOE_Executive_Preview.pdf].
14. Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi
R, Segal R: Nature of preventable adverse drug events in hos-
pitals: A literature review.  Am J Health-Syst Pharm 2003,
60:1750-9.
15. Winterstein AG, Johns TE, Rosenberg EI, Hatton RC, Gonzalez-Rothi
R, Kanjanarat P: Nature and causes of clinically significant med-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2008, 8:153 http://www.biomedcentral.com/1471-2334/8/153
Page 10 of 10
(page number not for citation purposes)
ication errors in a tertiary care hospital.  Am J Health-Syst Pharm
2004, 61:1908-16.
16. Kilbridge PM, Campbell UC, Cozart HB, Mojarrad MG: Automated
surveillance for adverse drug events at a community hospital
and an academic medical center.  J Am Med Inform Assoc 2006,
13:372-7.
17. Keystone JS, Kozarsky PE, Freedman DO: Internet and computer-
based resources for travel medicine practitioners.  Clin Infect
Dis 2001, 32:757-765.
18. McGregor JC, Weekes E, Forrest GN, Standiford HC, Perencevich
EN, Furuno JP, et al.: Impact of a computerized clinical decision
support system on reducing inappropriate antimicrobial use:
a randomized controlled trial.  J Am Med Inform Assoc 2006,
13:378-384.
19. Miller SM, Beattie MM, Butt AA: Personal digital assistant infec-
tious diseases applications for health care professionals.  Clin
Infect Dis 2003, 36:1018-29.
20. Belgado BS, Hatton RC, Doering PL: Evaluation of electronic
drug information resources for answering questions
received by decentralized pharmacists.  Am J Health-Syst Pharm
1997, 54:2592-6.
21. Clauson KA, Seamon MJ, Clauson AS, Van TB: Evaluation of drug
information databases for personal digital assistants.  Am J
Health Syst Pharm 2004, 61:1015-24.
22. Kupferberg N, Jones Hartel L: Evaluation of five full-text drug
databases by pharmacy students, faculty, and librarians: do
the groups agree?  J Med Libr Assoc 2004, 92:66-71.
23. Clauson KA, Marsh WA, Polen HH, Seamon MJ, Ortiz BI: Clinical
decision support tools: analysis of online drug information
databases.  BMC Med Inform Decis Mak 2007, 7:7.
24. Morbidity and Mortality Weekly Report (MMWR)   [http://
www.cdc.gov/mmwR/]
25. Centers for Disease Control and Prevention (CDC)   [http://
www.cdc.gov]
26. Mandell GL, Bennett JE, Dolin R: Principles and Practices of Infectious
Diseases 6th edition. Oxford: Church Livingstone; 2004. 
27. Natural Medicine Comprehensive Database (NMCD)   [http:/
/www.naturaldatabase.com]
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/8/153/pre
pub